In DepthTranslational Research

Medical centers spearhead China's pharma push

See allHide authors and affiliations

Science  10 Nov 2017:
Vol. 358, Issue 6364, pp. 709
DOI: 10.1126/science.358.6364.709

You are currently viewing the summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

Summary

China’s pharma industry has limited R&D capabilities. Struggling under heavy patient loads, clinicians have little time for research and academics are under pressure to churn out peer-reviewed papers. As a result, universities have spun off few biotech ventures. Also hindering innovation are a slow regulatory review process and lax intellectual property protection. Now, China is endeavoring to raise its game in biomedicine. It’s launching five new translational medicine centers, each showered with $150 million in startup funds for buildings and instruments. And last month, China issued guidelines for overhauling the nation’s drug approval process by reforming clinical trial management, speeding reviews, allowing submission of foreign clinical trial data, and promoting innovation in drug and medical device development.